D:A:D Study
The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) was a prospective multi-cohort study that focused on the potential association between antiretroviral drugs and cardiovascular disease, liver and renal disease, and non-AIDS-defining malignancies.
Funding for the D:A:D study ceased as of 1 February 2016. For the time being, scientific productivity continues based on the last available joint dataset.
Publications related to the D:A:D study in 2017 include:
Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals
Ryom L, Mocroft A, Kirk O, Reiss P, Ross M, Smith C, Moranne O, Morlat P, Fux CA, Sabin C, Phillips A, Law M, Lundgren JD; D:A:D study group.
AIDS. 2017 Mar 28. doi: 10.1097/QAD.0000000000001464. [Epub ahead of print]
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study
Boyd MA, Mocroft A, Ryom L, Monforte AD, Sabin C, El-Sadr WM, Hatleberg CI, De Wit S, Weber R, Fontas E, Phillips A, Bonnet F, Reiss P, Lundgren J, Law M.
PLoS Med. 2017 Nov 7;14(11):e1002424. doi: 10.1371/journal.pmed.1002424. eCollection 2017 Nov
Differences in virological and immunological risk factors for non-Hodgkin and Hodgkin lymphoma
Shepherd L, Ryom L, Law M, Hatleberg CI, de Wit S, Monforte AD, Battegay M, Phillips A, Bonnet F, Reiss P, Pradier C, Grulich A, Sabin C, Lundgren J, Mocroft A.
J Natl Cancer Inst. 2017 Dec 18. doi: 10.1093/jnci/djx249. [Epub ahead of print]
